eClinical Technology and Industy News

Second Genome Announces Research Collaboration with Virginia Commonwealth University to Identify a Non-Invasive NASH Composite Biomarker

Second Genome, leveraging machine learning capabilities and patient samples from studies led by VCU School of Medicine Professor Dr. Arun Sanyal, to identify microbiome signals to diagnose patients with NASH who have advanced fibrosis

BRISBANE, Calif., Sept. 23, 2021 /PRNewswire/ — Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, today announced it entered into a research collaboration with Virginia Commonwealth University (VCU) to generate a non-invasive stool-based composite biomarker for non-alcoholic steatohepatitis (NASH).  

Under the terms of the agreement, Second Genome will utilize its proprietary sg-4sight discovery engine’s machine learning capabilities to identify a composite biomarker that can diagnose patients with NASH who have advanced fibrosis. The lab of Dr. Arun Sanyal, Professor of Medicine, Physiology and Molecular Pathology at VCU School of Medicine, will provide geographically diverse patient samples, clinical meta-data, liver biopsy images and a biorepository. Second Genome will characterize the gastrointestinal microbial taxa and microbial transcriptome in NASH and non-alcoholic fatty liver disease (NAFLD) patients, identify the composite biomarker and then clinically validate the model in patients who are enrolled from the biorepository or other studies conducted by Dr. Sanyal.

“Our proprietary machine learning capabilities facilitate more efficient organization and analysis of microbial insights to further our understanding of a broad range of diseases,” said Nicole Narayan, Ph.D., Head of NASH Biomarker Discovery at Second Genome. “We look forward to applying our sg-4sight platform through this collaboration with Dr. Arun Sanyal and his team on generating a composite biomarker for NASH.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives